The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi that the ...
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the region's ...